Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

Kandi Technologies Shares Spike Higher Following Tweet From Co. ‘Kandi is Ready!’

https://twitter.com/kandiamerica/status/1408455039815933954

byMichael Horton

June 25, 2021

1 minute read

Kandi is ready! #NeighborhoodElectricVehicle pic.twitter.com/Rh9TZgTIuf

— Kandi America (@kandiamerica) June 25, 2021

Autoliv Shares Slide On Q1 Miss, FY22 Outlook Cut

By Shivani Kumaresan

April 22, 8:28 AM

Autoliv Inc (NYSE:ALV) reported a first-quarter FY22 sales decline of 5.3% year-on-year to $2.12 billion, missing the consensus of $2.18 billion.…

ALV

$100 Invested In Nike 20 Years Ago Would Be Worth This Much Today

By Benzinga Insights

July 15, 2:01 PM

Nike (NYSE:NKE) has outperformed the market over the past 20 years by 7.42% on an annualized basis producing an average annual return of 15.59%. Currently, Nike has a market capitalization of $165.23 billion.

NKE

Moleculin Biotech Reports Began Dosing In Volunteers For Phase 1a Trial Of Co.’s WP1122 For Treatment Of COVID

By Benzinga Newsdesk

May 26, 8:36 AM

– Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose – – Multiple ascending dose (MAD) cohort to

MBRX

B of A Securities Maintains Underperform on Evergy, Raises Price Target to $67

By Vick Meyer

January 22, 1:21 PM

B of A Securities maintains Evergy (NYSE:EVRG) with a Underperform and raises the price target from $64 to…

EVRG

Kandi Technologies Shares Spike Higher Following Tweet From Co. ‘Kandi is Ready!’

Related Posts

Autoliv Shares Slide On Q1 Miss, FY22 Outlook Cut

$100 Invested In Nike 20 Years Ago Would Be Worth This Much Today

Moleculin Biotech Reports Began Dosing In Volunteers For Phase 1a Trial Of Co.’s WP1122 For Treatment Of COVID

B of A Securities Maintains Underperform on Evergy, Raises Price Target to $67